Antibody halts cachexia from cancer

New research raises the prospect of more effective treatments for cachexia, a profound wasting of fat and muscle occurring in about half of all cancer patients, raising their risk of death. In mice bearing lung tumors, their symptoms of cachexia improved or were prevented when given an antibody that blocked the effects of a protein, PTHrP, secreted by the tumor cells. PTHrP stands for parathyroid hormone-related protein, and is known to be released from many types of cancer cells.

Many strategies have been tried to reverse cachexia, which may cause such frailty that patients cannot endure potentially life-saving treatments, but none have had great success. The scientists from Dana-Farber Cancer Institute in Boston, Massachusetts, said their findings are the first to explain in detail how PTHrP from tumors switches on a thermogenic (heat-producing) process in fatty tissues, resulting in unhealthy weight loss. Their study, led by Bruce Spiegelman, PhD, was reported in Nature (2014; doi:10.1038/nature13528).

This tumor-derived protein, they found, stimulated beige or brown fat cells mixed with stored white fat in the body, causing the white fat to brown—that is, generate heat and cause weight loss even when the animals were at rest.

The researchers carried out two experiments using mice that developed lung tumors and cachexia. In one, they administered a polyclonal antibody that specifically neutralizes PTHrP and found that it prevented the wasting almost completely, while untreated animals became mildly cachexic.

In a second experiment, the antibody treatment prevented the loss of muscle mass and improved muscle function, while control animals developed severe muscle-wasting.

"You would have expected, based on our first experiments in cell culture, that blocking PTHrP in the mice would reduce browning of the fat," said Spiegelman. "But we were surprised that it also affected the loss of muscle mass and improved health."

The research suggested that PTHrP alone does not directly cause muscle wasting, yet blocking the protein's activity prevents it. Thus, the role of PTHrP "is definitely not the whole answer" to the riddle of cachexia, noted Spiegelman, but may be a necessary part, while other factors are also involved.

An analysis of the blood of 47 patients with lung or colon cancer who were cachexic found increased levels of PTHrP in 17 of the patients. Those patients had significantly lower lean body mass and were producing more heat energy at rest than were the other patients in the group.

It may turn out that the PTHrP mechanism is responsible for cachexia in a subset, but not all, cancer patients, Spiegelman suggested. Before trying the anti-PTHrP antibody in human patients, he said, "clinicians would probably first want to find out if the protein is elevated in certain cancers, and determine which patients would be good candidates for a clinical trial."

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs